🔎 Trials Near Me

Home › Major Depressive Disorder › NCT07924852

Neuromodulation of Motivation and Reward Oscillations

RecruitingHealthy volunteers welcome

Delta and Theta-Frequency Transcranial Alternating Stimulation Neuromodulation of Motivation and Reward Oscillations in Disorder of Reward Dysfunction.

Who can join

Ages 18 to 55 · All sexes · Healthy volunteers welcome

Full eligibility criteria
Inclusion Criteria (General):

* Aged between 18 - 55 years old.
* Able to provide informed consent
* Have normal to corrected vision
* Willing to comply with all study procedures and be available for the duration of the study
* Speak and understand English.
* Negative THC saliva test and alcohol breathalyzer at all lab visits.
* Negative UTOX for any substance other than THC.

Exclusion Criteria (General):

* Mania history (Bipolar I, or current mania).
* Psychosis history.
* Current suicide intent (score \>4 on C-SRSS, or intent \>0 on SRA)
* Current moderate-to-severe SUD or AUD (Except CUD and nicotine for NEMO-CUD).
* Current pregnancy.
* Seizure, neurological conditions, or brain surgery history.
* Implanted medical devices (e.g., cochlear implants, cardiac pacemakers).
* Change in psychotropic medication in the past 3 months (i.e., medication needs to be stable for 12 weeks).
* Use of seizure threshold lowering medication (e.g., Stimulants, Benzos, SNRIs, Antipsychotics \[Adderall, Vyvanse, Xanax, Wellbutrin, Cymbalta, Lithium\] - SSRIs not exclusionary).

Specific CUD Inclusion:

* Avg. 6+ cannabis use days per week over the past 3-months, and 24+ cannabis use days in the past 30 days.
* Primary delta-9 or THC-A cannabis flower or vape concentrate user.
* Current moderate-to-severe CUD (4+ criteria in the past year, at least one criterion other than craving must be met in the past three months).
* Cannabis is the primary substance of use (Nicotine dependence is allowable)
* Not currently receiving treatment for cannabis, planning to immediately quit or reduce use.
* Lifetime history of MDE/PDD must have lifetime anhedonia symptom and/or heavy cannabis user (3+ sessions daily for at least past year including the past 3-months and past 30 days).

Specific MDD Inclusion:

* Current MDE diagnosis.
* No lifetime history of severe SUD.
* No current moderate-to-severe SUD.
* 100% of NEMO-MDD participants elevated anhedonia on TEPS-C (i.e., 32 or lower on TEPS-C subscale).

Specific Control Inclusion:

* No current or historical psychiatric diagnosis.

About the study

Cannabis use disorder (CUD) and major depressive disorder (MDD) are among the most prevalent psychiatric conditions in the United States, affecting an estimated 20.6 million and 21 million adults respectively. Both disorders are characterized by anhedonia, diminished motivation, and blunted neural reward sensitivity. This shared dysregulated reward-processing may reflect a common prefrontal oscillatory dysfunction, centralized in mesolimbic dopaminergic reward pathways. This proposed project aims to investigate if transcranial alternating current (tACS) can modulate motivational behaviours and neural reward responsivity in participants with MDD and/or CUD during an effortful reward task. The investigators hypothesize that delta transcranial alternating current stimulation will produce a greater neural reward responsivity (RewP), and motivational behaviour during an effortful reward task.

What is being tested

Sponsor: Florida State University · Participants: 54 · Started: Nov 1, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07924852

Locations in the U.S.

FloridaThe BRAINS Lab at Florida State University, Tallahassee (Not yet recruiting)
The Riddle Lab at Florida State University, Tallahassee

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.